Trial reportRetina (Philadelphia, Pa.)2026
Association of Patient Age with Response to Anti-Vascular Endothelial Growth Factor Agents for Treatment of Diabetic Macular Edema.
Trial report in Retina (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeExplore the association of patient baseline age with response to anti-vascular endothelial growth factor treatment for diabetic macular edema.
methodsOne thousand six eyes assigned to anti-vascular endothelial growth factor treatment in 3 DRCR Retina Network randomized trials for diabetic macular edema were included. Age was classified into four levels: younger than 50, 50 to 59, 60 to 69, and 70 years or older. The associations between age with change in visual acuity and central subfield thickness from baseline and with weak treatment response in visual acuity and central subfield thickness not meeting prespecified thresholds over 2 years were assessed, controlling for trial, anti-vascular endothelial growth factor agent, and potential confounders.
resultsAt 2 years, the average improvement from baseline decreased with older age for visual acuity (youngest to oldest: +17.9 to +9.0 letters; P < 0.001) and central subfield thickness (-183 µ m to -158 µ m; P = 0.02). The cumulative proportion of weak response in visual acuity (60%-84%; P < 0.001) and central subfield thickness (42%-62%; P = 0.009) increased with older age. These trends were present in all anti-vascular endothelial growth factor subgroups.
conclusionLess improvement from baseline and greater likelihood of weak treatment response in visual acuity and central subfield thickness were observed among older patients. These findings may help refine expectations of treatment outcomes when initiating anti-vascular endothelial growth factor therapy for diabetic macular edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.